Navigation path

Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information

Xaliproden hydrochloride

EU orphan designation number: EU/3/00/015
Active ingredient: Xaliproden hydrochloride
Indication: Treatment of amyotrophic lateral sclerosis
Sponsor: Sanofi-Aventis
174 avenue de France, 75013 Paris, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/01/2001 Orphan designation EMEA/OD/029/00 (2001)109 of 17/01/2001
02/06/2006 Change of name and/or address of sponsor
03/05/2010 Removal of orphan designation from Community Register